Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K27ac and BRD4-binding regions in a clear cell renal cell carcinoma cell line, OS-RC-2

ABSTRACT: H3K27ac and BRD4-binding regions in a clear cell renal cell carcinoma cell line, OS-RC-2

PROVIDER: PRJNA542708 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9050700.fastq.gz	Fastqsanger.gz
	SRR9050701.fastq.gz	Fastqsanger.gz
	SRR9050702.fastq.gz	Fastqsanger.gz
	SRR9050693.fastq.gz	Fastqsanger.gz
	SRR9050703.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

RNA-sequencing of a clear cell renal cell carcinoma cell line, OS-RC-2

Project description:RNA-sequencing of a clear cell renal cell carcinoma cell line, OS-RC-2

| PRJNA542706 | ENA

H3K27ac and BRD4-binding regions in a clear cell renal cell carcinoma cell line, OS-RC-2

Project description:Advanced clear cell renal cell carcinoma (ccRCC) frequently causes systemic inflammation. Here, we identified the functional role and regulatory mechanism of inflammation driven by advanced ccRCC cells. The inflammatory nature of advanced ccRCC was recapitulated in a preclinical model of ccRCC. Amplification of cancer cell-intrinsic inflammation during ccRCC progression triggered neutrophil-dependent lung metastasis. Massive expression of inflammation-related genes was transcriptionally activated by epigenetic remodelling through mechanisms such as DNA demethylation and super-enhancer formation. Bromodomain and extra-terminal motif inhibitor (BETi) synchronously suppressed C–X–C-type chemokines in ccRCC cells and decreased neutrophil-dependent lung metastasis. Overall, our findings shed insight into the nature of inflammatory ccRCC, which triggers metastatic cascades, and suggest a potential therapeutic strategy.

2020-10-28 | GSE131139 | GEO

RNA-sequencing of neutrophils derived from OS-RC-2-bearing mice

Project description:RNA-sequencing of neutrophils derived from OS-RC-2-bearing mice

| PRJNA542707 | ENA

RNA-sequencing in OS-RC-2 cells under the knockdown of Arkadia or ESRP2

Project description:Tumor-specific alternative splicing is implicated in the progression of cancer, including clear cell renal cell carcinoma (ccRCC). Using ccRCC RNA-sequencing data from The Cancer Genome Atlas, we found that epithelial splicing regulatory protein 2 (ESRP2), one of the key regulators of alternative splicing in epithelial cells, is expressed in ccRCC. ESRP2 mRNA expression did not correlate with the overall survival rate of ccRCC patients, but the expression of some ESRP-target exons correlated with the good prognosis and with the expression of Arkadia (also known as RNF111) in ccRCC. Arkadia physically interacted with ESRP2, induced polyubiquitination, and modulated its splicing function. Arkadia and ESRP2 suppressed ccRCC tumor growth in a coordinated manner. Lower expression of Arkadia correlated with advanced tumor stages and poor outcomes in ccRCC patients. This study thus reveals a novel tumor-suppressive role of the Arkadia-ESRP2 axis in ccRCC. Expression of mRNA in a ccRCC cell line OS-RC-2 under the knockdown of Arkadia or ESRP2. Knock-down of ESRP2 was confirmed by RT-PCR because of low expression of ESRP2 which resulted in non-quantitative FPKM value.

2015-08-01 | E-GEOD-66741 | biostudies-arrayexpress

Time sensitive contribution of the BCAA catabolism to the TCA cycle carbons in HK2, 786-O, OS-RC-2 and RFX-631

Project description:The objective of this experiment is to test the contribution of the branched chain amino acids catabolism to the carbons used in the TCA cycle. To test this hypothesis, we incubated human renal epithelial cells (HK2) and ccRCC cell lines (786-O, 786-M1A, OS-RC-2, OS-LM1, RFX-631) with 13C6-leucine and 13C6-isoleucine in Plasmax media for 10 mins, 1 hour and 3 hours. Data were generated from 5 independent cultures. This is Part 4 of the study and the experiment number is MS52.

2022-07-15 | ST002225 | MetabolomicsWorkbench

RNA-sequencing of a clear cell renal cell carcinoma cell line, OS-RC-2

2020-10-28 | GSE131137 | GEO

Burkholderia pseudomallei OS strain:OS

Project description:Burkholderia pseudomallei OS strain:OS Genome sequencing and assembly

| PRJNA188496 | ENA

Gene expression profile at single cell level of cells from OS tissue of OS lung metastatic patient

Project description:The tumor microenvironment remains unclear in OS lung metastatic patient. We used single cell RNA-seq to analyze the non-immune and immune landscape of the tumor microenvironment in OS patients.

2024-01-17 | GSE234187 | GEO

Oryza sativa strain:OS suspension cell

Project description:Genome-wide analysis of cleavage sites in OS suspension cell (Rice)

| PRJDB7270 | ENA

transcriptome studies of BRD4 inhibitor BDF-1253 on renal clear carcinoma 786-O cells

Project description:As an epigenetic reader, BRD4 is important for the recognition of acetylated lysines and regulation of transcription. As BRD4 regulates the expression of several survival genes, such as c-Myc and Bcl-2, which is vital for the survival of tumor cells, then it is closely involved in various kinds of cancers. Accumulating evidence has proven that BRD4 could serve as a novel anti-cancer pharmaceutical target, and small-molecular BRD4 inhibitors have promising potentials in the treatment of BRD4-related cancers and other diseases. In this study, a novel category of BRD4 inhibitors, which are originated from an approved drug Nitroxoline and its analogues, were synthesized and evaluated by biochemical and cellular assays, as well as the method of crystallography and xenograft mice models. In renal cell carcinoma cell lines, these compounds exhibited efficient inhibition against the expression and protein abundance of BRD4 downstream genes. Moreover, the complex crystal structures of several compounds in this series with the first bromodomain of BRD4 were solved, which revealed the binding mechanism of this novel category of BRD4 inhibitors and facilitated further structural modifications. This series of novel BRD4 inhibitors is promising to become drug candidates for the treatment of renal cell carcinoma after further development and assessments.

2018-03-01 | GSE109870 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data